 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...6789101112131415161718» |
- |||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Feb 4, 2019
P3, N=212, Active, not recruiting, Sponsor: Pharmacyclics LLC.
Trial primary completion date: Oct 2017 --> Mar 2018
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 10, 2019
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Oct 2017 --> Mar 2018 Trial completion date: Dec 2018 --> Sep 2019
- ||||||| Leukeran (chlorambucil) / GSK
Trial completion: Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (clinicaltrials.gov) - Jan 8, 2019
P3, N=450, Completed, Sponsor: Celgene
Trial completion date: Dec 2018 --> Sep 2019 Active, not recruiting --> Completed
- || Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=49, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 26, 2018
P3, N=445, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2018 --> Aug 2018
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 12, 2018
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Nov 2018 --> Aug 2018 Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Sep 2018 --> Nov 2019
- | Gazyva (obinutuzumab) / Roche, Biogen
Trial completion, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 29, 2018
P3, N=979, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Sep 2018 --> Nov 2019 Active, not recruiting --> Completed
- | Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 11, 2018
P3, N=232, Active, not recruiting, Sponsor: Pharmacyclics LLC.
Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Apr 2023 | Trial primary completion date: Nov 2018 --> Apr 2023
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Oct 11, 2018
P1, N=38, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2018 --> Apr 2023 | Trial primary completion date: Nov 2018 --> Apr 2023 Active, not recruiting --> Completed
- | Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Trial completion date, Monotherapy: COMPLEMENT 1: Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 7, 2018
P3, N=447, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2018
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Enrollment change: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Jul 6, 2018
P1, N=38, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2018 Recruiting --> Active, not recruiting | N=60 --> 38
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
New trial: GAIRI: Gazyva Infusion Reaction Investigation (clinicaltrials.gov) - May 21, 2018
P=N/A, N=104, Recruiting, Sponsor: Healthy Future
- || lenalidomide / Generic mfg.
Trial completion date, Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Apr 26, 2018
P2, N=254, Active, not recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting | N=60 --> 38 Trial completion date: Mar 2018 --> Jul 2019 | Trial primary completion date: Mar 2018 --> Oct 2018
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Mar 30, 2018
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2018 --> Jul 2019 | Trial primary completion date: Mar 2018 --> Oct 2018 Trial completion date: Mar 2019 --> Sep 2018 | Trial primary completion date: Mar 2019 --> Sep 2018
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Phase classification: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Mar 29, 2018
P, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2019 --> Sep 2018 | Trial primary completion date: Mar 2019 --> Sep 2018 Phase classification: P=N/A --> P
- Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 20, 2018
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Phase classification: P=N/A --> P Trial completion date: Dec 2017 --> Dec 2018
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial: GLOW: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov) - Mar 11, 2018
P3, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || lenalidomide / Generic mfg.
Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Dec 4, 2017
P2, N=254, Active, not recruiting, Sponsor: Celgene
Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 24, 2017
P3, N=232, Active, not recruiting, Sponsor: Pharmacyclics LLC.
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Feb 2018 --> Nov 2018
- ||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Enrollment closed, Enrollment change, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 19, 2017
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Feb 2018 --> Nov 2018 Recruiting --> Active, not recruiting | N=450 --> 600
- | Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting --> Active, not recruiting | N=450 --> 600 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Oct 2019 --> Apr 2020
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Aug 22, 2017
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2019 --> Apr 2020 Trial primary completion date: Mar 2018 --> Mar 2019
- |||| Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 31, 2017
P3, N=979, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Oct 2018 --> Dec 2016
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 15, 2017
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Oct 2018 --> Dec 2016 Trial primary completion date: Mar 2017 --> Nov 2017
- || lenalidomide / Generic mfg.
Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Apr 25, 2017
P2, N=254, Active, not recruiting, Sponsor: Celgene
Trial primary completion date: Mar 2017 --> Nov 2017 Trial primary completion date: Mar 2017 --> Dec 2017
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Feb 20, 2017
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- ||||| Calquence (acalabrutinib) / AstraZeneca
Enrollment closed, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Feb 16, 2017
P3, N=535, Active, not recruiting, Sponsor: Acerta Pharma BV
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Mar 2017
- | Rituxan (rituximab) / Roche
Enrollment change: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Nov 2, 2016
P4, N=18, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2016 --> Mar 2017 N=26 --> 18
- ||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 18, 2016
P3, N=979, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=26 --> 18 Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New trial: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Sep 26, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 2, 2016
P3, N=445, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Leukeran (chlorambucil) / GSK
Trial completion, Metastases: Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 11, 2016
P3, N=205, Completed, Sponsor: German CLL Study Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed, Trial primary completion date, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Jul 28, 2016
P2, N=112, Active, not recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016
- |||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Trial primary completion date, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jul 20, 2016
P3, N=950, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016 Active, not recruiting --> Recruiting | Trial primary completion date: May 2016 --> Oct 2018
- Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Active, not recruiting --> Recruiting | Trial primary completion date: May 2016 --> Oct 2018 Trial primary completion date: Sep 2015 --> Sep 2016
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial primary completion date, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 31, 2016
P3, N=450, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Mar 2018 --> Sep 2018
- | Rituxan (rituximab) / Roche
Trial completion: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - May 6, 2016
P4, N=26, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Sep 2018 Active, not recruiting --> Completed
- ||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 5, 2016
P3, N=978, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Calquence (acalabrutinib) / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Apr 27, 2016
P3, N=510, Recruiting, Sponsor: Acerta Pharma BV
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Dec 2019
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Apr 6, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2019 --> Dec 2019 Trial primary completion date: Sep 2017 --> Mar 2018
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 3, 2016
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Sep 2017 --> Mar 2018 Trial primary completion date: Feb 2016 --> Aug 2016
- |||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Enrollment open, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 15, 2016
P3, N=450, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Feb 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- |||||||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
New P3 trial, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 24, 2015
P3, N=450, Not yet recruiting, Sponsor: TG Therapeutics, Inc.
- Rituxan (rituximab) / Roche
Trial primary completion date: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Nov 10, 2015
P4, N=26, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2019 --> Feb 2016
- ||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Oct 30, 2015
P3, N=212, Active, not recruiting, Sponsor: Pharmacyclics
Trial primary completion date: Feb 2019 --> Feb 2016 Recruiting --> Active, not recruiting
- Ukoniq (umbralisib) / TG Therap
Enrollment closed, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 8, 2015
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Trial primary completion date: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Sep 29, 2015
P3, N=232, Active, not recruiting, Sponsor: Pharmacyclics
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2018